• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Viral immunology >Immunogenicity and protective efficacy in mice and hamsters of a beta-propiolactone inactivated whole virus SARS-CoV vaccine.
【24h】

Immunogenicity and protective efficacy in mice and hamsters of a beta-propiolactone inactivated whole virus SARS-CoV vaccine.

机译：β-丙内酯灭活的全病毒SARS-CoV疫苗在小鼠和仓鼠中的免疫原性和保护功效。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The immunogenicity and efficacy of beta-propiolactone (BPL) inactivated whole virion SARS-CoV (WI-SARS) vaccine was evaluated in BALB/c mice and golden Syrian hamsters. The vaccine preparation was tested with or without adjuvants. Adjuvant Systems AS01(B) and AS03(A) were selected and tested for their capacity to elicit high humoral and cellular immune responses to WI-SARS vaccine. We evaluated the effect of vaccine dose and each adjuvant on immunogenicity and efficacy in mice, and the effect of vaccine dose with or without the AS01(B) adjuvant on the immunogenicity and efficacy in hamsters. Efficacy was evaluated by challenge with wild-type virus at early and late time points (4 and 18 wk post-vaccination). A single dose of vaccine with or without adjuvant was poorly immunogenic in mice; a second dose resulted in a significant boost in antibody levels, even in the absence of adjuvant. The use of adjuvants resulted in higher antibody titers, with the AS01(B)-adjuvanted vaccine being slightly more immunogenic than the AS03(A)-adjuvanted vaccine. Two doses of WI-SARS with and without Adjuvant Systems were highly efficacious in mice. In hamsters, two doses of WI-SARS with and without AS01(B) were immunogenic, and two doses of 2 mug of WI-SARS with and without the adjuvant provided complete protection from early challenge. Although antibody titers had declined in all groups of vaccinated hamsters 18 wk after the second dose, the vaccinated hamsters were still partially protected from wild-type virus challenge. Vaccine with adjuvant provided better protection than non-adjuvanted WI-SARS vaccine at this later time point. Enhanced disease was not observed in the lungs or liver of hamsters following SARS-CoV challenge, regardless of the level of serum neutralizing antibodies.
机译：在BALB / c小鼠和金色叙利亚仓鼠中评估了β-丙内酯（BPL）灭活的全病毒颗粒SARS-CoV（WI-SARS）疫苗的免疫原性和功效。在有或没有佐剂的情况下测试疫苗制剂。选择佐剂系统AS01（B）和AS03（A）并测试其对WI-SARS疫苗引起高体液和细胞免疫应答的能力。我们评估了疫苗剂量和每种佐剂对小鼠免疫原性和功效的影响，以及有或没有AS01（B）佐剂的疫苗剂量对仓鼠的免疫原性和功效的影响。通过在早期和晚期（接种疫苗后4周和18周）用野生型病毒攻击来评估功效。含有或不含佐剂的单剂疫苗在小鼠中的免疫原性很差。即使没有佐剂，第二剂也可显着提高抗体水平。佐剂的使用导致更高的抗体滴度，其中AS01（B）佐剂的疫苗比AS03（A）佐剂的疫苗具有更高的免疫原性。有和没有佐剂系统的两剂WI-SARS在小鼠中都非常有效。在仓鼠中，含和不含AS01（B）的两剂WI-SARS具有免疫原性，含或不含佐剂的两剂2杯WI-SARS具有完全的免疫原性。尽管在第二次接种后18周的所有接种仓鼠组中抗体滴度均下降，但是仍然部分保护了接种仓鼠免受野生型病毒攻击。在此较晚的时间点，佐剂疫苗比未佐剂的WI-SARS疫苗提供更好的保护。不论血清中和抗体水平如何，SARS-CoV攻击后在仓鼠的肺或肝脏中均未观察到疾病增强。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号